介质细胞 stromal 细胞 (MSCs) 对类型 1 ex vivo 细胞因子原始化的差异反应:对MSC治疗的影响

Andre J Burnham1, Elisabetta M Foppiani1, Kyndal L Goss2

  • 1Department of Pediatrics, Marcus Center for Pediatric Cellular Therapy, Aflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia, USA.

Cytotherapy
|October 10, 2023
PubMed
概括

与干扰素- (IFN-γ) 进行介质细胞 stromal 细胞 (MSC) 的初始化,可以提高它们针对T细胞的免疫抑制疗法的潜力,与TNF-α初始化不同. 这项研究有助于开发更有效的MSC治疗方法.